Radiation Therapy

  • July 25, 2016 — Varian Medical Systems announced last week that Varex Imaging Corp. will be the name for its Imaging Components business upon the completion of the planned spin-off of that business as a new, stand-alone public company via a tax-free distribution to Varian stockholders.
  • The U.S. Food and Drug Administration (FDA) recently approved the first focused ultrasound device to treat essential tremor in patients who have not responded to medication.
  • An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) unveiled a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete...
  • In recent years, intraoperative radiation therapy (IORT) has been growing in acceptance in the U.S. as an alternative to traditional external beam radiation therapy (EBRT) for patients with early-stage breast cancer. For patients meeting appropriate selection criteria, the benefits are clear —...
  • cardio-oncology, echo strain assessment
    Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat cancer patients for the second leading cause of death among cancer survivors — cardiovascular disease brought on by their treatments.
brain metastases, stereotactic radiosurgery, whole brain radiation therapy, JAMA study
News | Radiation Therapy | July 26, 2016
July 26, 2016 — A new study shows that patients with brain metastases can be treated in an effective and substantiall
Varian, Varex Imaging Corp., components, new name, spinoff
News | Imaging | July 25, 2016
July 25, 2016 — Varian Medical Systems announced last week that Varex Imaging Corp.
ASTRO, clinical practice statement update, rectal cancer, radiation therapy
News | Radiation Therapy | July 22, 2016
The American Society for Radiation Oncology (ASTRO) recently issued a new clinical practice statement for the treatment...
PTW New York, BeamScan water phantom, radiation therapy, dosimetry, AAPM 2016
Technology | Radiation Therapy | July 21, 2016
July 21, 2016 — PTW New York announced it will display its Beamscan technology and the latest advancements in radiati
News | Clinical Decision Support | July 15, 2016
The National Comprehensive Cancer Network (NCCN), an alliance of 27 of the nation’s leading cancer centers, has been...
InSightec, ExAblate Neuro, MRI-guided focused ultrasound device, essential tremor, FDA

Image courtesy of InSightec

Technology | Focused Ultrasound Therapy | July 11, 2016
The U.S. Food and Drug Administration (FDA) recently approved the first focused ultrasound device to treat essential...
News | Radiation Therapy | July 11, 2016
A new study assed the rates of laryngeal preservation and laryngectomy-free survival in patients receiving the...
Feature | Treatment Planning | July 06, 2016 | Melinda Taschetta-Millane
Treatment planning systems are at the heart of radiation therapy (RT) and the key to improved patient outcomes. Once...
IBA, Institute Curie, proton therapy, experimental research beam line, install
News | Proton Therapy | July 05, 2016
IBA (Ion Beam Applications S.A.) and the Institute Curie in Paris, France, announced the signature of an agreement for...
Accuray, Radixact Treatment Delivery Platform, image-guided radiation therapy, IGRT, FDA clearance
Technology | Image Guided Radiation Therapy (IGRT) | June 30, 2016
Accuray Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its...
blood test, PRRT, neuroendocrine tumors, NETs, somatostatin receptor imaging, SRI, SNMMI 2016 study

NET circulating transcript and chromogranin A (CgA) levels in responders and non-responders. a) Transcripts were significantly reduced at 6-month follow-up compared to pre-treatment values. Non-responders (NR) exhibited significantly elevated levels at 6 months (FUP_6m). This was also significantly higher than in responders (R). b) A significant alteration was noted only for CgA in non-responders (NR) at 6 months. c) Pre-PRRT: NET transcript scores were elevated in 94 percent and CgA in 57 percent. d) Responders: NET transcripts decreased in 88 percent of responders (no change in 12 percent). CgA was unchanged in 47 percent, decreased in 21 percent and was elevated in 32 percent. e) Non-Responders: NET transcripts increased in 90 percent (no change in 10 percent). CgA was unchanged in 33 percent, decreased in 40 percent and was elevated in 27 percent. For NET transcripts, no falsely decreased or increased values occurred in responders or non-responders, respectively. Credit: LuGenIum Consortium for Independent Research & Wren Laboratories

News | Oncology Diagnostics | June 23, 2016
Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor...
neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

News | Nuclear Imaging | June 23, 2016
Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering force linked to...
pretargeted radioimmunotherapy, PIRT, colorectal cancer, radionuclide agents, SNMMI 2016, Sarah Cheal

Illustration of three-step DOTA-PRIT based on targeting with an IgG-scFv bispecific antibody (e.g., huA33-C825 for detection and treatment of colorectal cancer) with dual specificity for a tumor-associated antigen (e.g., GPA33) and M-DOTA haptens (e.g., Lu-177 DOTA). Image courtesy of Memorial Sloan Kettering Cancer Center.

News | Radiopharmaceuticals and Tracers | June 20, 2016
An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of...
immunotherapy, checkpoint inhibitors, University of Chicago study, radiation therapy, vaccination
News | Radiation Therapy | June 13, 2016
June 13, 2016 — By combining local radia...
Fraunhofer MEVIS, radiation therapy efficiency, SPARTA project
News | Radiation Therapy | June 09, 2016
The Fraunhofer Institute for Medical Image Computing MEVIS in Bremen, Germany, recently completed a project to develop...
lung cancer, oliogometastases, progression-free survival, LCT, MD Anderson
News | Lung Cancer | June 06, 2016
Lung cancer patients with oliogometastases may benefit from aggressive local therapy, surgery or radiation, after...
News | Image Guided Radiation Therapy (IGRT) | June 06, 2016
Elekta and Philips announced the installation of a third high-field (1.5 Tesla) magnetic resonance-guided linear...
Novocure, METIS trial, Optune, Tumor Treating Fields, TTFields, NSCLC, lung cancer
News | Lung Cancer | June 03, 2016
June 3, 2016 — Novocure announced that the U.S.
Elekta, Leksell Gamma Knife Icon, Japan, United States, U.S. approval, radiosurgery system
News | Radiation Therapy | June 03, 2016
June 3, 2016 — Elekta announced that its Leksell Gamma Knife Icon...
University Hospitals Cleveland, proton therapy center, Mevion, Ohio
News | Proton Therapy | June 02, 2016
University Hospitals in Cleveland recently held a ceremony to mark the completion of its new $30 million proton therapy...
Overlay Init